Profund Advisors LLC Acquires 17,132 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Profund Advisors LLC raised its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 153.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 28,297 shares of the biotechnology company’s stock after acquiring an additional 17,132 shares during the period. Profund Advisors LLC’s holdings in Sarepta Therapeutics were worth $4,471,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in SRPT. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 160.0% in the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock valued at $457,221,000 after buying an additional 2,917,797 shares during the period. Farallon Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after buying an additional 1,243,427 shares during the period. Norges Bank bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at $80,697,000. Bank of Nova Scotia bought a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at $50,990,000. Finally, Avoro Capital Advisors LLC raised its stake in shares of Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after buying an additional 319,444 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Insider Transactions at Sarepta Therapeutics

In other news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares in the company, valued at approximately $3,467,243.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Ryan Edward Brown sold 38,957 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now owns 17,129 shares of the company’s stock, valued at approximately $2,768,217.69. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. In the last three months, insiders sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Price Performance

SRPT opened at $127.21 on Friday. The stock has a 50-day moving average price of $137.26 and a 200-day moving average price of $132.66. Sarepta Therapeutics, Inc. has a 12-month low of $55.25 and a 12-month high of $173.25. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $12.02 billion, a P/E ratio of 1,156.45 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. During the same period in the prior year, the business earned ($0.27) EPS. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities analysts predict that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on SRPT shares. Piper Sandler decreased their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. UBS Group boosted their price objective on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. BMO Capital Markets boosted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday, June 24th. Bank of America boosted their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research note on Friday, June 21st. Finally, Morgan Stanley reiterated an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Three analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $187.39.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.